Diversity versus concentration in antipsychotic drug selection

Journal of Mental Health Policy and Economics

Volumn 11, Issue 3, 2008, Pages 107-112

  Leslie, Douglas L ^a   Rosenheck, Robert A ^b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Northeast Program Evaluation Center   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; DRUG CHOICE; DRUG COST; DRUG USE; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE NEED; HERFINDAHL INDEX; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH; PRESCRIPTION; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM;

ANTIPSYCHOTIC AGENTS; CHOICE BEHAVIOR; DRUG PRESCRIPTIONS; HUMANS; MEDICAL AUDIT; PHYSICIAN'S PRACTICE PATTERNS; SCHIZOPHRENIA;

EID: 51049114264     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
3. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, et al. Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia. JAMA 2003; 290: 2693-2702.
4. Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, Belmaker RH. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 2001; 62 (Suppl 2): 28-34.
5. Huskamp HA. Managing psychotropic drug costs: will formularies work? Health Aff (Millwood) 2003; 22: 84-96.
6. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003; 64: 580-588.
7. Simon GE, Psaty BM, Hrachovec JB, Mora M. Principles for evidence-based drug formulary policy. J Gen Intern Med 2005; 20: 964-968.
8. Frank RG, Zeckhauser RJ. Custom-made versus ready-to-wear treatments: behavioral propensities in physicians' choices. J Health Econ 2007; 26: 1101-1127.
9. Stem S, Trajtenberg M. Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking. NBER Working Paper Series. Cambridge, MA; 1998:1-44.
10. Rosenheck R, Doyle J, Leslie D, Fontana A. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull 2003; 29: 81-93.
11. Rosenheck R, Leslie D. Administrative prescription review procedures and use of atypical antipsychotic medications in the Department of Veterans Affairs. Ment Health Serv Res 2003; 5: 149-153.
12. U.S. General Accounting Office. VA health care: Implementation of prescribing guideline for atypical antipsychotic drugs generally sound. Washington, DC; 2002.
13. Semyak MJ, Leslie D, Rosenheck R. Predictors of antipsychotic medication change. J Behav Health Serv Res 2005; 32: 85-94.
14. Rosenheck R, Desai R, Steinwachs D, Lehman A. Benchmarking Treatment of Schizophrenia: A Comparison of Service Delivery by the National Government and by State and Local Providers. J Nerv Ment Dis 2000; 188: 209-216.